Quick Answer
Vera Therapeutics, Inc. reported Operating Income of -$315.47 million for fiscal year 2025.
Vera Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$315.47M | -88.7% |
| 2024 | -$167.17M | -63.9% |
| 2023 | -$102.01M | -12.2% |
| 2022 | -$90.90M | -164.2% |
| 2021 | -$34.40M | +34.1% |
| 2020 | -$52.24M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$83.93M | -68.5% | -4.7% |
| June 30, 2025 | -$80.14M | -114.6% | -40.1% |
| March 31, 2025 | -$57.19M | -83.8% | -14.8% |
| September 30, 2024 | -$49.80M | -128.9% | -33.4% |
| June 30, 2024 | -$37.34M | -70.0% | -20.0% |
| March 31, 2024 | -$31.11M | +0.5% | -43.0% |
| September 30, 2023 | -$21.76M | +13.8% | +1.0% |
| June 30, 2023 | -$21.97M | -45.9% | +29.7% |
- Vera Therapeutics, Inc. showed a decrease of -88.7% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Vera Therapeutics, Inc.’s operating income has declined by 503.9% (from -$52.24 million to -$315.47 million).
- The most recent figure is from Vera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: